🇺🇸 FDA

Drug profile · INN

mifepristone

CORLUXIN

approved Not yet assigned
US status
approved
Patents linked
8
News articles
0

Quick answer

mifepristone (CORLUXIN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN mifepristone
Brand CORLUXIN
Route ORAL
Formulation TABLET
ATC code Not yet assigned
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 11173165

    Optimizing mifepristone levels for Cushing's patients

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10842801

    Optimizing mifepristone absorption

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10660904

    Optimizing mifepristone levels for cushing's patients

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10500216

    Optimizing mifepristone absorption

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10166243

    Optimizing mifepristone levels for cushing'S patients

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10166242

    Optimizing mifepristone levels for Cushing's patients

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9943526

    Optimizing mifepristone levels for cushing's patients

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8921348

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is mifepristone?

mifepristone (CORLUXIN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for mifepristone?

CORLUXIN is a marketed brand name for mifepristone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of mifepristone?

mifepristone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.